Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies.

被引：0
|
作者：
Attard, G
Plummer, RE
De Bono, JS
Bale, C
Fong, P
Barrett, M
Fox, NL
Howard, T
Ullrich, S
Calvert, H
机构：
[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[2] No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
[3] Human Genome Sci, Rockville, MD USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9060S / 9060S
页数：1
相关论文
共 50 条
  • [1] Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.
    Pacey, S
    Plummer, RE
    Attard, G
    Bale, C
    Calvert, AH
    Blagden, S
    Fox, NL
    Corey, A
    de Bono, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 205S - 205S
  • [2] HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.
    Patnaik, A.
    Wakelee, H.
    Mita, M.
    Fitzgerald, A.
    Hill, M.
    Fox, N.
    Howard, T.
    Ullrich, S.
    Tolcher, A.
    Sikic, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 123S - 123S
  • [3] HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors.
    Sarantopoulos, J
    Wakelee, H
    Mita, M
    Fitzgerald, A
    Hill, M
    Fox, NL
    Howard, T
    Ullrich, S
    Tolcher, AW
    Sikic, B
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9104S - 9104S
  • [4] A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies.
    Mom, CH
    Sleijfer, S
    Gietema, JA
    Sneller, V
    Fox, NL
    Lo, L
    Uges, DR
    Loos, W
    de Vries, EG
    Verweij, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9117S - 9117S
  • [5] Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
    Wakelee, H. A.
    Patnaik, A.
    Sikic, B. I.
    Mita, M.
    Fox, N. L.
    Miceli, R.
    Ullrich, S. J.
    Fisher, G. A.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 376 - 381
  • [6] A phase I and pharmacological study of HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies.
    Hariharan, S
    Gore, L
    Eckhardt, S
    Chow, L
    Eppers, S
    O'Bryant, C
    Padavic, K
    Fox, NL
    Lo, L
    Chesser, N
    Cohen, RB
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9058S - 9059S
  • [7] TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
    Taro Tamada
    Daisuke Shinmi
    Masahiro Ikeda
    Yasushi Yonezawa
    Shiro Kataoka
    Ryota Kuroki
    Eiji Mori
    Kazuhiro Motoki
    Scientific Reports, 5
  • [8] A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
    Hotte, Sebastien J.
    Hirte, Hal W.
    Chen, Eric X.
    Siu, Lillian L.
    Le, Lyly H.
    Corey, Alfred
    Iacobucci, Anne
    MacLean, Martha
    Lo, Larry
    Fox, Norma Lynn
    Oza, Amit M.
    CLINICAL CANCER RESEARCH, 2008, 14 (11) : 3450 - 3455
  • [9] TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
    Tamada, Taro
    Shinmi, Daisuke
    Ikeda, Masahiro
    Yonezawa, Yasushi
    Kataoka, Shiro
    Kuroki, Ryota
    Mori, Eiji
    Motoki, Kazuhiro
    SCIENTIFIC REPORTS, 2015, 5
  • [10] Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies
    Mom, C. H.
    Sleijfer, S.
    Gietema, J. A.
    Fox, N. L.
    Piganeau, C.
    Lo, L.
    Uges, D. R. A.
    Loos, W.
    de Vries, E. G. E.
    Verweij, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 63 - 63
12345